| Trastuzumab studied in …STUDIED_INderived200 of 795show all (up to 200) |
|---|
| → studied in | NCT02465060Phase 2 · active not recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) · 795 trials list this drug (178 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm,Lymphoma,Malignant Solid Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05132582Phase 3 · active not recruiting A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer · 795 trials list this drug (178 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07007559Phase 2 · recruiting ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00295893Phase 2 · active not recruiting Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02390427Phase 1 · completed Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03716180Phase 1 · active not recruiting DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05152147Phase 3 · active not recruiting A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers · 795 trials list this drug (178 active) | — | — | Gastric Neoplasm,Esophageal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06123338Phase 2 · recruiting A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer · 795 trials list this drug (178 active) | — | — | Malignant Esophageal Neoplasm,Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07407920Phase 2 · recruiting Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial · 795 trials list this drug (178 active) | — | — | Early Stage HER2-Positive Breast Carcinoma,Early Stage Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03367676Phase 2 · terminated 12 weekS Adjuvant dOcetaxel Plus trastuzumaB in Patients With Small, Node-negative, HER2-positive Breast cancER (SOBER) · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07315750Phase 3 · recruiting A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. · 795 trials list this drug (178 active) | — | — | Gastric Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07829900completed First-Line Dual Versus Single HER2-Targeted Therapy With Docetaxel for Advanced HER2-Positive Breast Cancer · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04208178Phase 3 · active not recruiting Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation · 795 trials list this drug (178 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07679269Phase 2 · not yet recruiting Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety. · 795 trials list this drug (178 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01613482Phase 3 · terminated TraStuzumAb-Radiotherapy : Impact on the Cerebral Prevention · 795 trials list this drug (178 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07824869Phase 2 · not yet recruiting A Phase II Study of HLX22 in Combination With Trastuzumab and Chemotherapy in HER2-Positive Locally Advanced or Metastatic Breast Cancer Patients · 795 trials list this drug (178 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06324357Phase 1/Phase 2 · recruiting Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm,Esophageal Adenocarcinoma,Gastric Adenocarcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05378464Phase 1 · suspended Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer · 795 trials list this drug (178 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06730373Phase 2 · recruiting First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2) · 795 trials list this drug (178 active) | — | — | Malignant Gastric Neoplasm,Gastric Carcinoma,HER2-Positive Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04266249Phase 2 · active not recruiting CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy · 795 trials list this drug (178 active) | — | — | Invasive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05081609Phase 1/Phase 2 · active not recruiting A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies · 795 trials list this drug (178 active) | — | — | Solid Neoplasm,Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06764875Phase 3 · recruiting A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer · 795 trials list this drug (178 active) | — | — | Gastroesophageal Junction Adenocarcinoma,HER2-Positive Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04661150Phase 2 · completed A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction · 795 trials list this drug (178 active) | — | — | Malignant Gastric Neoplasm,Gastroesophageal Junction Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04721977Phase 2 · active not recruiting A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001) · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05715931Phase 2 · active not recruiting Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma · 795 trials list this drug (178 active) | — | — | Gastric Adenocarcinoma,Gastroesophageal Junction Adenocarcinoma,HER2-Positive Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06625775Phase 1 · recruiting Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors · 795 trials list this drug (178 active) | — | — | Adult Solid Neoplasm,Malignant Breast Neoplasm,Malignant Lung Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03006172Phase 1 · active not recruiting To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer · 795 trials list this drug (178 active) | — | — | Solid Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04873362Phase 3 · active not recruiting A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04886531Phase 2 · recruiting Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06649331Phase 2 · recruiting Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm,Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07413939Phase 2/Phase 3 · recruiting RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive · 795 trials list this drug (178 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06876714Phase 3 · recruiting ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab · 795 trials list this drug (178 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07216105Phase 1 · recruiting FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm,Head and Neck Squamous Cell Carcinoma,Lung Non-Small Cell Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07797218Phase 3 · recruiting Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBC · 795 trials list this drug (178 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07795424Phase 2 · not yet recruiting Culmerciclib Combined With Letrozole and Dual HER2 Blockade as Neoadjuvant Therapy for HR+/HER2+ Breast Cancer · 795 trials list this drug (178 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00781612Phase 2 · active not recruiting A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies · 795 trials list this drug (178 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04379596Phase 2 · active not recruiting Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) · 795 trials list this drug (178 active) | — | — | Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03448042Phase 1 · active not recruiting A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers · 795 trials list this drug (178 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03615326Phase 3 · completed Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) · 795 trials list this drug (178 active) | — | — | Gastric Neoplasm,Gastroesophageal Junction Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03644186Phase 2 · completed To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH) · 795 trials list this drug (178 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06891833Phase 2/Phase 3 · recruiting A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer · 795 trials list this drug (178 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07788196Phase 2 · recruiting A Clinical Study Comparing Anti-HER2 Therapy Combined With Chemotherapy to Chemotherapy Alone as Adjuvant Therapy Following Surgery for Stage IB-II Gastric Cancer With High HER2 Expression. · 795 trials list this drug (178 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07102381Phase 2 · recruiting A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03417544Phase 2 · completed Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC · 795 trials list this drug (178 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04579380Phase 2 · active not recruiting Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations · 795 trials list this drug (178 active) | — | — | Urinary Tract Neoplasm,Lung Non-Small Cell Carcinoma,Uterine Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06441890Phase 2 · recruiting BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07779538Phase 3 · not yet recruiting Clinical Trials Comparing Trastuzumab Plus Bevacizumab With Bevacizumab as First-line Maintenance Therapy for Epithelial Ovarian Cancer · 795 trials list this drug (178 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04893109Phase 2 · recruiting ATEMPT 2.0: Adjuvant T-DM1 vs TH · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07772245Phase 2 · not yet recruiting Trial of Retifanlimab With Trastuzumab and Pertuzumab Combination in HER2-Addicted Breast Cancer · 795 trials list this drug (178 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04158258completed A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05408845Phase 2 · recruiting Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers · 795 trials list this drug (178 active) | — | — | Malignant Major Salivary Gland Neoplasm,Salivary Gland Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07766772Phase 2 · not yet recruiting Trastuzumab Rezetecan Followed by Pyrotinib, and Trastuzumab Combined With Capecitabine as First-line Treatment for Advanced HER2-positive Breast Cancer · 795 trials list this drug (178 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01937117Phase 2 · active not recruiting Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00770809Phase 3 · completed Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm,Male Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02320435Phase 3 · active not recruiting A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial · 795 trials list this drug (178 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05113251Phase 3 · active not recruiting Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer · 795 trials list this drug (178 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06731478Phase 3 · recruiting Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer · 795 trials list this drug (178 active) | — | — | Gastric Neoplasm,Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06439693Phase 2 · recruiting The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02654119Phase 2 · completed Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04784715Phase 3 · active not recruiting Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) · 795 trials list this drug (178 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06136897Phase 2 · active not recruiting Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J) · 795 trials list this drug (178 active) | — | — | Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07196774Phase 3 · active not recruiting A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer · 795 trials list this drug (178 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03304080Phase 1/Phase 2 · active not recruiting Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast · 795 trials list this drug (178 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02252887Phase 2 · completed Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy · 795 trials list this drug (178 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07683754Phase 3 · not yet recruiting T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05253651Phase 3 · recruiting A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer · 795 trials list this drug (178 active) | — | — | Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07716046Phase 2 · not yet recruiting Fulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for HR+/HER2+ Advanced Breast Cancer · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03414658Phase 2 · active not recruiting The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04285671Phase 1/Phase 2 · active not recruiting Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer · 795 trials list this drug (178 active) | — | — | Lung Neoplasm,Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07386938Phase 3 · active not recruiting A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05458674Phase 2 · active not recruiting Tucatinib+Trastuzumab+Eribulin in HER2+ MBC · 795 trials list this drug (178 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07694986Phase 2 · recruiting Trial of Therapies With IT cDC1s Combined w/ IT Trastuzamab for Her+ or IT Nivolumab for Her- BC LMD · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm,Leptomeningeal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03747120Phase 2 · active not recruiting Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP] · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06747338Phase 3 · active not recruiting A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer · 795 trials list this drug (178 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06239467Phase 1 · active not recruiting First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer · 795 trials list this drug (178 active) | — | — | Malignant Neoplasm,Solid Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00317720Phase 1/Phase 2 · completed Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer · 795 trials list this drug (178 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03179904Phase 2 · completed TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer · 795 trials list this drug (178 active) | — | — | Breast Carcinoma,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05376878Phase 4 · recruiting An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis · 795 trials list this drug (178 active) | — | — | Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01750073Phase 2 · completed Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm,Invasive Breast Carcinoma,Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01273610Phase 2 · active not recruiting Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer · 795 trials list this drug (178 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07666724completed Oncology Treatment Related Ocular Surface Changes · 795 trials list this drug (178 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00520975Phase 3 · terminated Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm,Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05323955Phase 2 · active not recruiting Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04188548Phase 1 · active not recruiting A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm,Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01730833Phase 2 · completed Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm,Breast Adenocarcinoma,Breast Inflammatory Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04928261Phase 4 · active not recruiting Evaluating 6-months of HER2-targeted Therapy in Patients With HER2 Positive Early-stage Breast Cancer That Achieve a Pathological Complete Response to Neoadjuvant Systemic Therapy · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06109467Phase 2 · active not recruiting Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer · 795 trials list this drug (178 active) | — | — | Gastric Neoplasm,Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06504732Phase 2/Phase 3 · recruiting To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer · 795 trials list this drug (178 active) | — | — | Solid Neoplasm,Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07518173Phase 3 · recruiting A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer · 795 trials list this drug (178 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01196390Phase 3 · completed Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer · 795 trials list this drug (178 active) | — | — | Malignant Esophageal Neoplasm,Esophageal Adenocarcinoma,Gastroesophageal Junction Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03199885Phase 3 · terminated Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer · 795 trials list this drug (178 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm,Breast Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05582499Phase 2 · recruiting Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy · 795 trials list this drug (178 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm,Early Stage Breast Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07610720Phase 2 · recruiting Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer · 795 trials list this drug (178 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07612215Phase 1/Phase 2 · recruiting Elacestrant in Advanced Triple Positive Breast Cancer · 795 trials list this drug (178 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03765983Phase 2 · terminated GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07578116Phase 3 · not yet recruiting Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis · 795 trials list this drug (178 active) | — | — | Oligometastatic Breast Carcinoma,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04296162Phase 2 · completed Oral Vinorelbine or Capecitabine Combined With Trastuzumab as Adjuvant Treatment for Patients With Lymph Node Negative, HER-2 Positive and Small Tumor Size Breast Cancer (ORCHID) · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04588545Phase 1/Phase 2 · active not recruiting Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease · 795 trials list this drug (178 active) | — | — | Leptomeningeal Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03125928Phase 2 · active not recruiting Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer · 795 trials list this drug (178 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06686394Phase 1/Phase 2 · recruiting Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009) · 795 trials list this drug (178 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04329065Phase 2 · recruiting Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer · 795 trials list this drug (178 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05615818Phase 3 · recruiting Personalized Medicine for Advanced Biliary Cancer Patients · 795 trials list this drug (178 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00896376NA · completed Trastuzumab in Treating Women With Metastatic Breast Cancer · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06663787active not recruiting Personalized Detection of ctDNA for Patients With HER2-Positive Metastatic Breast Cancer Patients Who Achieved Durable Response to Anti-HER2 Treatment · 795 trials list this drug (178 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05672524Phase 2 · recruiting A Study of Tucatinib and Trastuzumab in People With Rectal Cancer · 795 trials list this drug (178 active) | — | — | Rectal Neoplasm,Malignant Rectal Neoplasm,Rectal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05319873Phase 1/Phase 2 · active not recruiting Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer · 795 trials list this drug (178 active) | — | — | Invasive Breast Carcinoma,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07220135Phase 2 · recruiting Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast Cancer · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03738553terminated Multiparametric MRI for Assessing Breast Cancer Response to Anti-HER2 Therapy · 795 trials list this drug (178 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07565324Phase 2 · not yet recruiting Phase II Study of Ultrasound and ctDNA Guided Neoadjuvant Systemic Therapy for Patients With HER2-positive Early Breast Cancer (UC HER Trial) · 795 trials list this drug (178 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06589830Phase 2 · recruiting TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer · 795 trials list this drug (178 active) | — | — | Colorectal Neoplasm,Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05187182Phase 1 · recruiting CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer · 795 trials list this drug (178 active) | — | — | Malignant Esophageal Neoplasm,Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07402473Phase 2 · recruiting Optimize Neoadjuvant Therapy in HER2-Positive Early-Stage Breast Cancer · 795 trials list this drug (178 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07545044Phase 2 · not yet recruiting A Study of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast Cancer · 795 trials list this drug (178 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03820141Phase 2 · active not recruiting Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07527806Phase 2 · not yet recruiting Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07528898Phase 2 · not yet recruiting Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study. · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02705859Phase 1 · completed Phase Ib/II Trial of coPANlisib in Combination With Trastuzumab in HER2-positive Breast Cancer. (Panther Study) · 795 trials list this drug (178 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07441460Phase 3 · recruiting A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer · 795 trials list this drug (178 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05785741Phase 1/Phase 2 · recruiting A Study of DB-1310 in Advanced/Metastatic Solid Tumors · 795 trials list this drug (178 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05515796Phase 2 · completed Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors · 795 trials list this drug (178 active) | — | — | Malignant Gastric Neoplasm,Malignant Rectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06031233Phase 4 · recruiting Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie · 795 trials list this drug (178 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07335081Phase 2 · recruiting ctDNA in HER2+ EBC Neoadjuvant Treatment · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04253561Phase 1 · completed Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05733689Phase 1 · recruiting Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial) · 795 trials list this drug (178 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05325632Phase 2 · recruiting Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab · 795 trials list this drug (178 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03523585Phase 3 · completed DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02] · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06532006Phase 3 · recruiting A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer · 795 trials list this drug (178 active) | — | — | Gastric Neoplasm,Malignant Gastric Neoplasm,HER2-Positive Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07421141Phase 2 · active not recruiting De-escalation of Neoadjuvant Treatment (Paclitaxel + HP) in Early HER2+ Breast Cancer · 795 trials list this drug (178 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07377643Phase 3 · recruiting IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer · 795 trials list this drug (178 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04430738Phase 2 · active not recruiting Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers · 795 trials list this drug (178 active) | — | — | Cholangiocarcinoma,Colorectal Carcinoma,Esophageal Adenocarcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06100874Phase 2 · active not recruiting A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN) · 795 trials list this drug (178 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06016387Phase 2 · recruiting Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study · 795 trials list this drug (178 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07193394Phase 2 · recruiting Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04024462Phase 3 · completed A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer · 795 trials list this drug (178 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01853748Phase 2 · completed T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial) · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07416409completed Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB2-Positive Breast Cancer · 795 trials list this drug (178 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02226276NA · active not recruiting Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02947685Phase 3 · active not recruiting Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer · 795 trials list this drug (178 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03101748Phase 1/Phase 2 · terminated Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm,Breast Carcinoma,Breast Inflammatory Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03365882Phase 2 · completed S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery · 795 trials list this drug (178 active) | — | — | Colon Adenocarcinoma,Colon Carcinoma,Malignant Colon Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05415215Phase 3 · completed A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm,Breast Inflammatory Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06435429Phase 3 · recruiting A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer · 795 trials list this drug (178 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05605509Phase 2 · completed RP-6306 in Patients With Advanced Cancer · 795 trials list this drug (178 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07393425Phase 2 · recruiting Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer · 795 trials list this drug (178 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01796197Phase 2 · completed Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06771622Phase 1/Phase 2 · active not recruiting Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors · 795 trials list this drug (178 active) | — | — | Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05062889Phase 2 · suspended Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients · 795 trials list this drug (178 active) | — | — | Colon Neoplasm,Malignant Colon Neoplasm,RAS Wild-Type Colon Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02057133Phase 1 · active not recruiting A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread · 795 trials list this drug (178 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07366840Phase 2/Phase 3 · not yet recruiting RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03368729Phase 1/Phase 2 · active not recruiting Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03879577Phase 2 · active not recruiting Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer · 795 trials list this drug (178 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06468280Phase 2 · recruiting Synergistic Effects of PD-1 Antibody and Chemotherapy/Targeted Therapy Followed by Surgery-centric Local Treatment in Patients With Limited-metastatic Gastric Cancer · 795 trials list this drug (178 active) | — | — | Gastric Neoplasm,Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07340398Phase 2 · recruiting Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer · 795 trials list this drug (178 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07332533Phase 2/Phase 3 · not yet recruiting A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer · 795 trials list this drug (178 active) | — | — | HER2-Positive Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06961331completed Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer. · 795 trials list this drug (178 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04290793Phase 2/Phase 3 · active not recruiting Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03095352Phase 2 · completed Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03199300active not recruiting Investigating Cardiovascular Adverse Events Related to Cancer Treatment · 795 trials list this drug (178 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05583110Phase 2 · terminated Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer · 795 trials list this drug (178 active) | — | — | Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06245356Phase 2 · recruiting Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer · 795 trials list this drug (178 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05786716Phase 2/Phase 3 · recruiting DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations · 795 trials list this drug (178 active) | — | — | Skin Neoplasm,Solid Neoplasm,Lung Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05180006Phase 2 · terminated Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01358877Phase 3 · completed A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07246317Phase 2 · not yet recruiting Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04193059Phase 3 · active not recruiting Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01373710Phase 1/Phase 2 · completed Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous Meningitis · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm,Meningeal Carcinomatosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03498521Phase 2 · completed A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site · 795 trials list this drug (178 active) | — | — | Malignant Neoplasm of Unknown Primary | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06328738Phase 1 · active not recruiting ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer · 795 trials list this drug (178 active) | — | — | Colorectal Neoplasm,Malignant Colorectal Neoplasm,HER2-Positive Breast Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04425018Phase 2 · active not recruiting MARGetuximab Or Trastuzumab (MARGOT) · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05800275Phase 2 · recruiting Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease · 795 trials list this drug (178 active) | — | — | Leptomeningeal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05041842Phase 2 · active not recruiting Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer · 795 trials list this drug (178 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02827877Phase 2 · active not recruiting Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01191697Phase 2 · completed CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer · 795 trials list this drug (178 active) | — | — | Malignant Esophageal Neoplasm,Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04419181Phase 2 · withdrawn Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer · 795 trials list this drug (178 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04108858Phase 1/Phase 2 · terminated Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer · 795 trials list this drug (178 active) | — | — | Breast Neoplasm,Breast Carcinoma,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03264547Phase 3 · completed A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05980481Phase 2/Phase 3 · active not recruiting A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer · 795 trials list this drug (178 active) | — | — | Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07187752NA · not yet recruiting Identification of HER2-Positive Breast Cancer Molecular Characterization and Subtypes · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05385705Phase 1 · terminated A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020 · 795 trials list this drug (178 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07179939Phase 2 · not yet recruiting Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study · 795 trials list this drug (178 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02514681Phase 3 · completed A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer · 795 trials list this drug (178 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05063786Phase 3 · active not recruiting Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET) · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05900206Phase 2 · recruiting Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03501979Phase 2 · terminated Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm,Leptomeningeal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06490536Phase 3 · recruiting The Sagittarius Trial · 795 trials list this drug (178 active) | — | — | Malignant Colon Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03588091Phase 3 · completed Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer · 795 trials list this drug (178 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07116824Phase 2 · not yet recruiting HB1801 Combined Treatment of HER2-positive Breast Cancer · 795 trials list this drug (178 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02003209Phase 3 · completed Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm,Hormone Receptor-Positive Breast Carcinoma,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05002127Phase 2/Phase 3 · active not recruiting A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) · 795 trials list this drug (178 active) | — | — | Malignant Gastric Neoplasm,Gastric Adenocarcinoma,Gastroesophageal Junction Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03013218Phase 1 · completed A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01) · 795 trials list this drug (178 active) | — | — | Malignant Neoplasm,Solid Neoplasm,Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02205047Phase 2 · completed Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma · 795 trials list this drug (178 active) | — | — | Gastric Neoplasm,Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07093931Phase 4 · not yet recruiting Efficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in HER-2 Positive Breast Cancer · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01772472Phase 3 · completed A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE) · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03755141Phase 2 · completed Efficacy and Safety of Trastuzumab Biosimilar (Herzuma®) Plus Treatment of Physician's Choice (TPC) in Patients With HER-2 Positive Metastatic Breast Cancer · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06886659Phase 1 · completed A Study to Compare PK, Immunogenicity and Safety of Trastuzumab of Incepta Pharmaceuticals Ltd With Trastuzumab (Roche) · 795 trials list this drug (178 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01275677Phase 3 · completed Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm,Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02436993Phase 2 · active not recruiting Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab · 795 trials list this drug (178 active) | — | — | Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07062263Phase 3 · recruiting Trastuzumab Plus Chemotherapy vs Chemotherapy Alone in First-line HER2 Positive Advanced Biliary Tract Cancer Patients · 795 trials list this drug (178 active) | — | — | Malignant Neoplasm,Biliary Tract Carcinoma,Malignant Biliary Tract Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03094052Phase 2 · completed Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib · 795 trials list this drug (178 active) | — | — | Malignant Breast Neoplasm,Breast Adenocarcinoma,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03767335Phase 1 · completed MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer · 795 trials list this drug (178 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |